Long-term Effects of Somatostatin Analogues in Rat GH-secreting Pituitary Tumor Cell Lines

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2021 Jun 15

PMID 34128215

Citations 6

Authors

A Dicitore

D Saronni

G Gaudenzi

S Carra

M C Cantone

M O Borghi

L Persani

G Vitale

Affiliations

Soon will be listed here.

Abstract

Purpose: First-generation somatostatin analogs, octreotide (OCT) and lanreotide, are the cornerstone for the medical treatment of growth hormone (GH)-secreting pituitary tumors. A new multireceptor analog, such as pasireotide (PAS), showed better activity than OCT in long-term treatment of patients with acromegaly, but modulation of intracellular key processes is still unclear in vitro. In this study, we evaluated the antitumor activity of OCT and PAS in two GH-secreting pituitary tumor cell lines, GH3 and GH4C1, after a long-term incubation.

Methods: The effects of PAS and OCT on the cell viability, cell cycle, apoptosis, GH secretion, and tumor-induced angiogenesis have been evaluated through a colorimetric method (MTS Assay), DNA flow cytometry with propidium iodide, and Annexin V-FITC/propidium iodide staining, ELISA assay and zebrafish platform, respectively.

Results: PAS showed a more potent antitumor activity compared to OCT in GH3 cell line exerted through inhibition of cell viability, perturbation of cell cycle progression, and induction of apoptosis after 6 days of incubation. A concomitant decrease in GH secretion has been observed after 2 days of incubation only with PAS. No effect on tumor-induced angiogenesis has been reported after treatment with OCT or PAS in zebrafish/tumor xenograft model.

Conclusion: Long-term incubation with PAS showed a more potent antitumor activity than that reported after OCT in GH3 cells, mainly modulated by a cell cycle perturbation and a relevant induction in apoptosis.

Citing Articles

Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study.

Dicitore A, Gaudenzi G, Carra S, Cantone M, Oldani M, Saronni D Cancers (Basel). 2023; 15(22).

PMID: 38001635 PMC: 10669991. DOI: 10.3390/cancers15225375.

PER2 integrates circadian disruption and pituitary tumorigenesis.

Guo L, Cen H, Weng J, He Y, Guo X, He D Theranostics. 2023; 13(8):2657-2672.

PMID: 37215573 PMC: 10196825. DOI: 10.7150/thno.82995.

Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies.

Vitale G, Carra S, Alessi Y, Campolo F, Pandozzi C, Zanata I Int J Mol Sci. 2023; 24(4).

PMID: 36835022 PMC: 9961914. DOI: 10.3390/ijms24043610.

Exploration of the Effects of TGF- Pathway-Based Pituitary Tumor of Rats on GH3 Cell Line after Intervention with Different Concentrations of TGZ.

Duan J, Hu C, Zhang Q, Zhu J Contrast Media Mol Imaging. 2022; 2022:7445042.

PMID: 36072638 PMC: 9402356. DOI: 10.1155/2022/7445042.

Modeling Lung Carcinoids with Zebrafish Tumor Xenograft.

Carra S, Gaudenzi G, Dicitore A, Cantone M, Plebani A, Saronni D Int J Mol Sci. 2022; 23(15).

PMID: 35897702 PMC: 9330857. DOI: 10.3390/ijms23158126.

References

Peverelli E, Mantovani G, Calebiro D, Doni A, Bondioni S, Lania A . The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation. Mol Endocrinol. 2007; 22(3):676-88. PMC: 5419615. DOI: 10.1210/me.2007-0068. View

Weckbecker G, Lewis I, Albert R, Schmid H, Hoyer D, Bruns C . Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003; 2(12):999-1017. DOI: 10.1038/nrd1255. View

Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S . Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006; 91(4):1397-403. DOI: 10.1210/jc.2005-2347. View

Puig-Domingo M, Marazuela M . Precision medicine in the treatment of acromegaly. Minerva Endocrinol. 2018; 44(2):169-175. DOI: 10.23736/S0391-1977.18.02937-1. View

Lehmann A, Kliewer A, Schutz D, Nagel F, Stumm R, Schulz S . Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor. Mol Cell Endocrinol. 2014; 387(1-2):44-51. DOI: 10.1016/j.mce.2014.02.009. View

Petersenn S, Farrall A, De Block C, Block C, Melmed S, Schopohl J . Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary. 2013; 17(2):132-40. PMC: 3942632. DOI: 10.1007/s11102-013-0478-0. View

Vitale G, Gaudenzi G, Dicitore A, Cotelli F, Ferone D, Persani L . Zebrafish as an innovative model for neuroendocrine tumors. Endocr Relat Cancer. 2013; 21(1):R67-83. DOI: 10.1530/ERC-13-0388. View

Carra S, Gaudenzi G . New perspectives in neuroendocrine neoplasms research from tumor xenografts in zebrafish embryos. Minerva Endocrinol. 2020; 45(4):393-394. DOI: 10.23736/S0391-1977.20.03371-4. View

Melmed S, Bronstein M, Chanson P, Klibanski A, Casanueva F, Wass J . A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018; 14(9):552-561. PMC: 7136157. DOI: 10.1038/s41574-018-0058-5. View

10.

Hofland L, Velkeniers B, vd Lely A, Van Koetsveld P, Kazemzadeh M, Waaijers M . Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels. Clin Endocrinol (Oxf). 1992; 37(3):240-8. DOI: 10.1111/j.1365-2265.1992.tb02317.x. View

11.

Katznelson L, Laws Jr E, Melmed S, Molitch M, Murad M, Utz A . Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(11):3933-51. DOI: 10.1210/jc.2014-2700. View

12.

Ferone D, de Herder W, Pivonello R, Kros J, Van Koetsveld P, de Jong T . Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab. 2008; 93(4):1412-7. DOI: 10.1210/jc.2007-1358. View

13.

Carra S, Foglia E, Cermenati S, Bresciani E, Giampietro C, Lora Lamia C . Ve-ptp modulates vascular integrity by promoting adherens junction maturation. PLoS One. 2012; 7(12):e51245. PMC: 3522677. DOI: 10.1371/journal.pone.0051245. View

14.

Bocci G, Culler M, Fioravanti A, Orlandi P, Fasciani A, Colucci R . In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. Eur J Clin Invest. 2007; 37(9):700-8. DOI: 10.1111/j.1365-2362.2007.01848.x. View

15.

Colao A, Grasso L, Giustina A, Melmed S, Chanson P, Pereira A . Acromegaly. Nat Rev Dis Primers. 2019; 5(1):20. DOI: 10.1038/s41572-019-0071-6. View

16.

Fuentes-Fayos A, Garcia-Martinez A, Herrera-Martinez A, Jimenez-Vacas J, Vazquez-Borrego M, Castano J . Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. Minerva Endocrinol. 2019; 44(2):109-128. DOI: 10.23736/S0391-1977.19.02970-5. View

17.

Hauser F, Meyerhof W, Wulfsen I, Schonrock C, Richter D . Sequence analysis of the promoter region of the rat somatostatin receptor subtype 1 gene. FEBS Lett. 1994; 345(2-3):225-8. DOI: 10.1016/0014-5793(94)00444-7. View

18.

Colao A, Auriemma R, Pivonello R . The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary. 2015; 19(2):210-21. PMC: 4799266. DOI: 10.1007/s11102-015-0677-y. View

19.

Colao A, Auriemma R, Lombardi G, Pivonello R . Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2010; 32(2):247-71. DOI: 10.1210/er.2010-0002. View

20.

Herrera-Martinez A, Hofland J, Hofland L, Brabander T, Eskens F, Galvez Moreno M . Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs. 2018; 79(1):21-42. PMC: 6338796. DOI: 10.1007/s40265-018-1033-0. View